Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Autologous T cells engineered to express a chimeric antigen receptor specific for the B-cell maturation antigen produced responses in the majority of patients with refractory and resistant myeloma, including deep molecular responses in 26% of treated patients. High-grade hematologic toxic effects an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-02, Vol.384 (8), p.705-716
Hauptverfasser: Munshi, Nikhil C, Anderson, Larry D, Shah, Nina, Madduri, Deepu, Berdeja, Jesús, Lonial, Sagar, Raje, Noopur, Lin, Yi, Siegel, David, Oriol, Albert, Moreau, Philippe, Yakoub-Agha, Ibrahim, Delforge, Michel, Cavo, Michele, Einsele, Hermann, Goldschmidt, Hartmut, Weisel, Katja, Rambaldi, Alessandro, Reece, Donna, Petrocca, Fabio, Massaro, Monica, Connarn, Jamie N, Kaiser, Shari, Patel, Payal, Huang, Liping, Campbell, Timothy B, Hege, Kristen, San-Miguel, Jesús
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antigens
Biomarkers - blood
Bone marrow
CD38 antigen
Cell therapy
Chimeric antigen receptors
Cytokine Release Syndrome - etiology
Cytokines
Drug dosages
Drug Resistance, Neoplasm
FDA approval
Female
Hematologic Diseases - chemically induced
Humans
Immunomodulation
Immunotherapy, Adoptive - adverse effects
Life Sciences
Lymphocytes
Lymphocytes B
Lymphocytes T
Male
Middle Aged
Minimal residual disease
Multiple myeloma
Multiple Myeloma - immunology
Multiple Myeloma - therapy
Neurotoxicity
Neutropenia
Pharmacokinetics
Progression-Free Survival
Proteasome inhibitors
Receptors, Chimeric Antigen - therapeutic use
Recurrence
Thrombocytopenia
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Autologous T cells engineered to express a chimeric antigen receptor specific for the B-cell maturation antigen produced responses in the majority of patients with refractory and resistant myeloma, including deep molecular responses in 26% of treated patients. High-grade hematologic toxic effects and cytokine release syndrome were common.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2024850